OncoMatch/Clinical Trials/NCT06712810
Q702 for the Treatment of Patients With Hematologic Malignancies
Is NCT06712810 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Axl/Mer/CSF1R Inhibitor Q702 for hematopoietic and lymphatic system neoplasm.
Treatment: Axl/Mer/CSF1R Inhibitor Q702 — This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Giving Q702 may be safe, tolerable and/or effective in treating patients with hematologic malignancies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Myeloproliferative Neoplasm
Primary Central Nervous System Lymphoma
Biomarker criteria
Excluded: BRAF activating alterations
without activating alterations in v-Raf murine sarcoma viral oncogene homolog B (BRAF) or Mitogen-activated protein kinase kinase (MAP2K) oncogenes
Excluded: MAP2K1 activating alterations
without activating alterations in v-Raf murine sarcoma viral oncogene homolog B (BRAF) or Mitogen-activated protein kinase kinase (MAP2K) oncogenes
Allowed: BRAF V600E
Relapsed/refractory patients with Erdheim-Chester disease or Langerhans histiocytosis who have received vemurafenib for BRAF V600E mutated disease
Allowed: MAP2K1 activating MAP2K alterations
Relapsed/refractory patients with Erdheim-Chester disease or Langerhans histiocytosis who have received...cobimetinib for disease with activating MAP2K alterations
Allowed: MAP2K1 activating MAPK pathway alteration
Relapsed/refractory patients with Rosai-Dorfman disease and an activating mitogen-activated protein kinase (MAPK) pathway alteration who have failed prior treatment with cobimetinib
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
Hemoglobin ≥ 8.0 g/dL; ANC ≥ 1.0 x 10^9/L; Platelets ≥ 80 x 10^9/L; WBC ≥ 2.5 x 10^9/L
Kidney function
Serum creatinine ≤ 1.5 x ULN and calculated creatinine clearance ≥ 50 mL/min (Cockcroft-Gault)
Liver function
Total bilirubin ≤ 1.5 x ULN; ALT, AST, ALP ≤ 2.5 x ULN (≤ 5 x ULN for patients with liver involvement)
Cardiac function
No New York Heart Association Class III or IV cardiac disease, myocardial infarction, severe unstable angina, coronary/peripheral artery bypass graft, congestive heart failure ≤ 6 months prior; QTcF ≤ 470 msec
Hemoglobin ≥ 8.0 g/dL; ANC ≥ 1.0 x 10^9/L; Platelet count ≥ 80 x 10^9/L; WBC ≥ 2.5 x 10^9/L; Total bilirubin ≤ 1.5 x ULN; ALT, AST, ALP ≤ 2.5 x ULN (≤ 5 x ULN for patients with liver involvement); Serum creatinine ≤ 1.5 x ULN and CrCl ≥ 50 mL/min; New York Heart Association Class III or IV cardiac disease, or myocardial infarction, severe unstable angina, coronary/peripheral artery bypass graft, congestive heart failure ≤ 6 months prior to registration; QTcF > 470 msec [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic in Arizona · Scottsdale, Arizona
- Mayo Clinic in Rochester · Rochester, Minnesota
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify